The Pharmacogenetics of Immunosuppression for Organ Transplantation: A Route to Individualization of Drug Administration

American Journal of PharmacoGenomics

Volumn 3, Issue 5, 2003, Pages 291-301

  Fredericks, Salim ^a   Holt, David W ^a   MacPhee, Iain A M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

DIABETES MELLITUS; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTESTINE ABSORPTION; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PHARMACOGENETICS;

EID: 0242428253     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303050-00001     Document Type: Review

References (148)

1. Matas AJ, Gillingham KJ, Chavers BM, et al. The importance of early cyclosporine levels in pediatric kidney transplantation. Clin Transplant 1996; 10 (6 Pt 1): 482-6
2. Cohen D, Galbraith C. General health management and long-term care of the renal transplant recipient. Am J Kidney Dis 2001; 38 (6 Suppl. 6): S10-24
3. Weir MR, Fink JC. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34 (1): 1-13
4. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66 (12): 1736-40
5. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66 (8): 1040-6
6. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr Opin Nephrol Hypertens 2002; 11 (6): 657-63
7. Holt DW, Armstrong VW, Griesmacher A, et al. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit 2002; 24 (1): 59-67
8. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001 Sep 27; 72 (6): 1024-32
9. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68 (1): 55-62
10. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24 (6): 472-95
11. Undre N, Moller A. Pharmacokinetic interpretation of FK506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. Transpl Int 1994; 7 Suppl. 1: S15-21
12. Sketris I, Yatscoff R, Keown P, et al. Optimizing the use of cyclosporine in renal transplantation. Clin Biochem 1995; 28 (3): 195-211
13. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996; 30 (2): 107-40
14. Lindholm A. Cyclosporine A: clinical experience and therapeutic drug monitoring. Ther Drug Monit 1995; 17 (6): 631-7
15. Kerman RH, Kimball PM, Lindholm A, et al. Immune risk factors: impact on the incidence and diagnosis of rejection. Transplant Proc 1993; 25 (4 Suppl. 3): 23-5
16. Zheng J, Sambol NC, Zimmerman J, et al. Population pharmacokinetics (PK) of sirolimus [abstract]. Clin Pharmacol Ther 1996; 59 Suppl. 2: S 150
17. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41 (11): 813-51
18. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporin after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57 (5): 485-91
19. Mueller EA, Kovarik JM, van Bree BJ, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11 (2): 301-4
20. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338 (8781): 1488-90
21. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001 Jan; 69 (1): 24-31
22. Rendic S, Di CF. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29 (1-2): 413-580
23. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97 (7): 3473-8
24. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 1999; 39: 1-17
25. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999; 39 (10): 995-1005
26. Christians U, Bleck JS, Lampen A, et al. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem? Transplant Proc 1996; 28 (4): 2159-61
27. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58 (1): 15-9
28. Gupta SK, Bakran A, Johnson RW, et al. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989; 27 (4): 475-81
29. Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52 (5): 453-7
30. Tuteja S, Alloway RR, Johnson JA, et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001 May 15; 71 (9): 1303-7
31. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22 (6): 947-55
32. Gerk PM, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther 2002 Aug; 302 (2): 407-15
33. Wahlberg J, Wilczek HE, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Transplantation 1995; 60 (7): 648-52
34. Kovarik JM, Mueller EA, van Bree BJ, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994; 58 (6): 658-63
35. Kovarik JM, Mueller EA, van Bree BJ, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83 (3): 444-6
36. d'Uscio CH, Aweeka FT, Prueksaritanont T, et al. Immunopharmacodynamic studies of cyclosporine in patients awaiting renal transplantation. J Clin Pharmacol 1995; 35 (10): 967-73
37. Yoshimura N, Kahan BD. Pharmacodynamic assessment of the in vivo cyclosporine effect on interleukin-2 production by lymphocytes in kidney transplant recipients. Transplantation 1985; 40 (6): 661-6
38. Awni WM. Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokinet 1992; 23 (6): 428-48
39. Hirano T, Oka K, Takeuchi H, et al. Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy. Clin Pharmacol Ther 1997; 62 (6): 652-64
40. Simpson MA, Young-Fadok TM, Madras PN, et al. Sequential interleukin 2 and interleukin 2 receptor levels distinguish rejection from cyclosporine toxicity in liver allograft recipients. Arch Surg 1991; 126 (6): 717-9
41. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001 Nov 14; 286 (18): 2270-9
42. Lennard L, van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46 (2): 149-54
43. Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 1997; 391: 14-21
44. Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17 (2): 102-5
45. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286 (5439): 487-91
46. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115 (4): 813-21
47. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34 (8): 1081-5
48. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111 (8): 641-9
49. Thervet E, Anglicheau D, Toledano N, et al. Long-term results of TMPT activity monitoring in azathioprine-treated renal allograft recipients. J Am Soc Nephrol 2001 Jan; 12 (1): 170-6
50. Soria-Royer C, Legendre C, Mircheva J, et al. Thiopurine-methyl-transferase activity to assess azathioprine myelotoxicity in renal transplant recipients. Lancet 1993; 341 (8860): 1593-4
51. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354 (9172): 34-9
52. Chocair PR, Duley JA, Simmonds HA, et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53 (5): 1051-6
53. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126 (8): 608-14
54. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19-52
55. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315 (1-2): 137-55
56. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12 (6): 429-36
57. Evans WE. Thiopurine S-methyhransferase deficiency: a genetic polymorphism that affects a small number of drugs in a big way. Pharmacogenetics 2002; 12: 421-3
58. Weinshiliboum R. Inheritance and drug response. New Engl J Med 2003; 348 (6): 529-37
59. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. New Engl J Med 2003; 348 (6): 538-49
60. Stronceck D, Procter J, Johnson J. Drug-induced hemolysis: cefotetan-dependent hemolytic anemia mimicking an acute intravascular immune transfusion reaction. Am J Hematol 2000; 64: 67-70
61. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270 (1): 414-23
62. Domanski TL, Finta C, Halpert JR, et al. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59 (2): 386-92
63. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus: gene evolution by capture of downstream exons. Gene 2000; 260 (1-2): 13-23
64. Karanam BV, Vincent SH, Newton DJ, et al. FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab Dispos 1994; 22 (5): 811-4
65. Gellner K, Eiselt R, Hustert E, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11 (2): 111-21
66. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60 (1): 14-24
67. Watkins PB. Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete? Hepatology 1995; 22 (3): 994-6
68. Koch I, Weil R, Wolbold R, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30 (10): 1108-14
69. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66 (3): 288-94
70. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998; 95 (22): 13176-81
71. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90 (16): 1225-9
72. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000 Jan; 67 (1): 48-56
73. Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002 Mar; 71 (3): 196-204
74. Westlind A, Lofberg L, Tindberg N, et al. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999; 259 (1): 201-5
75. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001 Jul; 11 (5): 447-58
76. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68 (1): 82-91
77. Rivory LP, Qin H, Clarke SJ, et al. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. Eur J Clin Pharmacol 2000 Aug; 56 (5): 395-8
78. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47 (6): 1048-52
79. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002 Mar; 12 (2): 121-32
80. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27 (4): 383-91
81. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002 Jul; 62 (1): 162-72
82. MacPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002 Dec 5; 74 (11): 1486-9
83. Paulussen A, Lavrijsen K, Bohets H, et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000 Jul; 10 (5): 415-24
84. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11 (9): 773-9
85. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2022; 48 (10): 1668-71
86. Kahan BD, Shaw LM, Holt D, et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990; 36 (8 Pt 1): 1510-6
87. Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264 (18): 10388-95
88. Johnston A, Chusney G, Schutz E, et al. Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2). Ther Drug Monit 2003; 25 (2): 167-73
89. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem 1999; 45 (3): 371-81
90. Morris RG, Ilett KF, Tett SE, et al. Cyclosporin monitoring in Australasia: 2002 update of consensus guidelines. Ther Drug Monit 2002; 24 (6): 677-88
91. Zaman GJ, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A 1994; 91 (19): 8822-6
92. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug trans-porter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98
93. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002 Jan; 2 (1): 48-58
94. Llorente L, Richaud-Patin Y, Diaz-Borjon A, et al. Multidrug resistance-1 (MDR1) in rheumatic autoimmune disorders: part I. Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000 Jan; 67 (1): 30-9
95. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000 Feb; 118 (2): 279-88
96. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003 Apr 10; 348 (15): 1442-8
97. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27 (2-3): 201-14
98. Kwei GY, Alvaro RF, Chen Q, et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdrla P-glycoprotein. Drug Metab Dispos 1999; 27 (5): 581-7
99. Wacher VJ, Silverman JA, Wong S, et al. Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly (ethylene glycol 1000) succinate. J Pharmacol Exp Ther 2002; 303 (1): 308-13
100. Paine MF, Leung LY, Lim HK, et al. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J Pharmacol Exp Ther 2002; 301 (1): 174-86
101. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97 (11): 2517-24
102. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70 (2): 189-99
103. Kim BR. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12: 425-7
104. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12 (6): 437-50
105. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889
106. Hashimoto Y, Sasa H, Shimomura M, et al. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm. Res 1998; 15 (10): 1609-13
107. Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69 (5): 308-16
108. Masuda S, Uemoto S, Hashida T, et al. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 2000 Jul; 68 (1): 98-103
109. Kaplan B, Lown K, Craig R, et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 1999; 67 (2): 333-5
110. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62 (3): 248-60
111. Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002 Jun; 24 (3): 400-4
112. Yokogawa K, Takahashi M, Tamai I, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdrla knockout mice. Pharm Pharm Res 1999; 16 (8): 1213-8
113. Sonneveld P, Durie BG, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin: the Leukaemia Group of the EORTC and the HOVON. Lancet 1992; 340 (8814): 255-9
114. Hauser IA, Koziolek M, Hopfer U, et al. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int 1998; 54 (4): 1139-49
115. Laplante A, Demeule M, Murphy GF, et al. Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp. Transplant Proc 2002 Dec; 34 (8): 3393-5
116. Jette L, Beaulieu E, Leclerc JM, et al. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 1996; 270 (5 Pt 2): F756-65
117. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27 (2-3): 161-70
118. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40 (3): 159-68
119. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27 (2): 161-6
120. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13 (3): 129-34
121. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002 Mar; 300 (3): 1036-45
122. Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first pass metabolism overemphazised? Pharmacol Rev 1999; 51: 135-58
123. Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002 Aug; 12 (6): 451-7
124. Schuetz EG, Umbenhauer DR, Yasuda K, et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 2000 Jan; 57 (1): 188-97
125. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359 (9300): 30-6
126. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101 (2): 289-94
127. Jones K, Hoggard PG, Sales SD, et al. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001; 15 (6): 675-81
128. Yamauchi A, Ieri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplatation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002; 74 (4): 571-8
129. Drach J, Gsur A, Hamilton G, et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88 (5): 1747-54
130. Randolph GJ, Beaulieu S, Pope M, et al. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci U S A 1998; 95 (12): 6924-9
131. Nakamoto T, Hase I, Imaoka S, et al. Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin. Pharmacogenetics 2000; 10 (6): 571-5
132. Andrews PA, Sen M, Chang RW. Racial variation in dosage requirements of tacrolimus. Lancet 1996; 348 (9039): 1446
133. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65 (4): 515-23
134. Felipe CR, Silva HT, Machado PG, et al. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin Transplant 2002 Aug; 16 (4): 262-72
135. Lindholm A, Welsh M, Alton C, et al. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52 (4): 359-71
136. Min DI, Lee M, Ku YM, et al. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 2000 Nov; 68 (5): 478-86
137. Pollak R, Wong RL, Chang CT. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients: Neoral Study Group. Ther Drug Monit 1999; 21 (6): 661-3
138. Stein CM, Sadeque AJ, Murray JJ, et al. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clin Pharmacol Ther 2001 May; 69 (5): 317-23
139. Vasquez EM, Benedetti E, Pollak R. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. Transplantation 2001 Jan 27; 71 (2): 229-33
140. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000 Jun; 40 (6): 624-33
141. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50
142. McLeod HL. Pharmacogenetics: more than skin deep. Nat Genet 2001 Nov; 29 (3): 247-8
143. Wood AJ. Racial differences in the response to drugs: pointers to genetic differences. N Engl J Med 2001 May 3; 344 (18): 1394-6
144. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001 May 3; 344 (18): 1351-7
145. Zhou HH, Koshakji RP, Silberstein DJ, et al. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989; 320 (9): 565-70
146. Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001 May 3; 344 (18): 1358-65
147. McLeod HL. Race and responsiveness to drugs for heart failure. N Engl J Med 2001 Sep 6; 345 (10): 766-7
148. Genes, drugs and race [editorial]. Nat Genet 2001 Nov; 29 (3): 239-40